Similar articles for PMID: 38195751

Year	Number of Results
2014	1
2018	8
2019	14
2020	12
2021	18
2022	31
2023	24
2024	9

1

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.

Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Levine BL, et al. Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w. Nat Med. 2024. PMID: 38195751 No abstract available.

2

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.

Sun W, Liang AB, Huang H, Huang XJ. Sun W, et al. Haematologica. 2023 Aug 1;108(8):2011-2028. doi: 10.3324/haematol.2022.282316. Haematologica. 2023. PMID: 36794504 Free PMC article. Review.

3

State of the art in CAR T cell therapy for CD19+ B cell malignancies.

Frigault MJ, Maus MV. Frigault MJ, et al. J Clin Invest. 2020 Apr 1;130(4):1586-1594. doi: 10.1172/JCI129208. J Clin Invest. 2020. PMID: 32235098 Free PMC article. Review.

4

Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.

Sun W, Jiang Z, Jiang W, Yang R. Sun W, et al. Cancer Treat Res Commun. 2022;33:100638. doi: 10.1016/j.ctarc.2022.100638. Epub 2022 Sep 22. Cancer Treat Res Commun. 2022. PMID: 36184307 Free article. Review.

5

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.

Roselli E, Faramand R, Davila ML. Roselli E, et al. J Clin Invest. 2021 Jan 19;131(2):e142030. doi: 10.1172/JCI142030. J Clin Invest. 2021. PMID: 33463538 Free PMC article. Review.

6

CAR-T cell therapy for patients with hematological malignancies. A systematic review.

Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R. Pasqui DM, et al. Eur J Haematol. 2022 Dec;109(6):601-618. doi: 10.1111/ejh.13851. Epub 2022 Sep 18. Eur J Haematol. 2022. PMID: 36018500 Review.

7

Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.

Liu H, Li P, Zhao A, Lei W, Liang A, Qian W. Liu H, et al. Leuk Lymphoma. 2022 Apr;63(4):1001-1004. doi: 10.1080/10428194.2021.2010062. Epub 2021 Nov 28. Leuk Lymphoma. 2022. PMID: 34842037 No abstract available.

8

Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.

Zhang G, Deng L, Lu H, Zhang W. Zhang G, et al. Int J Clin Pharm. 2024 Feb;46(1):186-194. doi: 10.1007/s11096-023-01670-1. Epub 2023 Dec 12. Int J Clin Pharm. 2024. PMID: 38087131

9

Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.

Halim L, Ajina A, Maher J. Halim L, et al. Best Pract Res Clin Haematol. 2018 Jun;31(2):117-125. doi: 10.1016/j.beha.2018.04.002. Epub 2018 Apr 21. Best Pract Res Clin Haematol. 2018. PMID: 29909912 Review.

10

Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.

Catalá E, Iacoboni G, Vidal-Jordana Á, Oristrell G, Carpio C, Vilaseca A, Cabirta A, Bosch F, Tintoré M, Barba P. Catalá E, et al. Hematol Oncol. 2022 Aug;40(3):482-487. doi: 10.1002/hon.2976. Epub 2022 Feb 16. Hematol Oncol. 2022. PMID: 35139240

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year